gms | German Medical Science

72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

06.06. - 09.06.2021

Correlation of Olig2 with tumour attachment to glioma stem cell zones in newly diagnosed glioblastoma patients

Korrelation von Olig2 mit der Tumoranhaftung an Gliomstammzellzonen bei Patienten mit neu diagnostiziertem Glioblastom

Meeting Abstract

  • presenting/speaker Ronja Löber-Handwerker - Universitätsmedizin Göttingen, Neurochirurgie, Göttingen, Deutschland
  • Katja Döring - Universitätsmedizin Göttingen, Neuroradiologie, Göttingen, Deutschland
  • Swetlana Sperling - Universitätsmedizin Göttingen, Neurochirurgie, Göttingen, Deutschland
  • Milena Ninkovic - Universitätsmedizin Göttingen, Neurochirurgie, Göttingen, Deutschland
  • Christine Stadelmann - Universitätsmedizin Göttingen, Neuropathologie, Göttingen, Deutschland
  • Bernd Alt-Epping - Universitätsmedizin Göttingen, Palliativmedizin, Göttingen, Deutschland
  • Veit Rohde - Universitätsmedizin Göttingen, Neurochirurgie, Göttingen, Deutschland
  • Vesna Malinova - Universitätsmedizin Göttingen, Neurochirurgie, Göttingen, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie. sine loco [digital], 06.-09.06.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocP033

doi: 10.3205/21dgnc321, urn:nbn:de:0183-21dgnc3213

Published: June 4, 2021

© 2021 Löber-Handwerker et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Objective: Glioma stem cells (GSC) are deemed to play a crucial role during the tumor invasion in glioblastoma (GBM) patients. The oligodendrocyte lineage transcription factor 2 (Olig2) is a highly specific GSC marker, which is increasingly gaining attention for the biomolecular GBM characterization among other well-established molecular markers such as MGMT (methylguanine methyltransferase)-methylation and IDH (isocitrate dehydrogenase)-mutation. However, its prognostic role is still not clear, and the literature reports are controversial. The aim of the study was to evaluate a possible correlation of Olig2 with GBM localization in relation to GSC zones

Methods: A retrospective analysis of patients with newly diagnosed GBM and treated at our department from 2016 to 2019 was performed. Information about different molecular markers such as IDH-mutation, MGMT-methylation, p53, Ki67 and Olig2 was gathered from the neuropathological reports. The localization of the tumor on the first magnetic resonance imaging (MRI) and relation to several GSC zones such as the subventricular (SVZ) and the subgranular zone (SGZ) was evaluated by reviewing the MRI scans.

Results: Of the 109 cases analyzed, 91 (83.49%) stained at least partially positive for Olig2 -our primary marker of interest. Only 6 (5.50%) showed an IDH-1 mutation. We further analysed MGMT status, tumor volume and relation to GSC zones. 44 GBMs (40.37%) demonstrated MGMT-methylation. Mean tumor volume on MRI scans was 31cm3. We found 62 (56.88%) had contact with a GSC zone. We performed correlation analysis and found a statistically significant positive correlation between tumor volume and contact to GCS zones (r=0.29; p=0.006). However, we could not demonstrate a positive correlation between Olig2 and contact to GSC zone.

Conclusion: Olig2 expression is a frequently found neuropathological parameter in newly diagnosed GBM, which showed no statistically significant correlation with tumor attachment to the GSC zones in this retrospective study. This might be due to the lack of further sub-differentiation of the Olig2-positive tumor cells regarding their phosphorylation. Consideration of the Olig2-phosphorylation-status may further shed light on the prognostic role of Olig2 in GBM patients by providing insight about different tumor invasion/proliferation pathways which we aim to further evaluate in a prospective study.